TRT8 min read
An optimal testosterone level—for which outcome?
Reference ranges describe populations. Treatment targets serve a clinical purpose. Neither establishes a universal number for energy, muscle and lifelong health.
Read articleBlog
Research, explained. Explore peptides, supplements, hormone health, longevity and red light therapy with clear, practical breakdowns of what the studies actually tell us.
Explore the articles
Find a topic you’re curious about and take a closer look.
TRT9 min read
TRT Evidence in Younger Men: Why Age Limits in Trials Matter
A study in older men can inform care without answering every question for a younger patient. Here is how age, diagnosis, fertility and follow-up change the evidence.
Read article
Peptides9 min read
Why a host-defense peptide is not automatically safe to inject
Natural origin does not establish injection safety. Read the human LL-37 exposure record, product-quality questions and the limits of topical evidence.
Read article
Supplements9 min read
Pre-workout formulas: ingredient studies are not a trial of the tub
A formula can increase perceived energy without improving the lifting outcome you care about. Read the evidence by product, endpoint and timescale.
Read article
Peptides8 min read
GHRP-2 in sport: the rules do not depend on whether it works for you
GHRP-2 is named on the 2026 and published 2027 WADA lists. Clinical use, sporting permission and laboratory detection each answer a different question.
Read article
TRT9 min read
When a TRT Study Reports “No Significant Difference”: What Does That Mean?
A nonsignificant result can be informative without proving two treatments identical. Real testosterone trials show how to read the outcome, uncertainty and study design.
Read article
Peptides9 min read
Weight-loss peptides: why lean mass and muscle are different claims
What STEP 1 and other human studies actually measured—and why lean mass, skeletal muscle, body-weight percentages and strength are different outcomes.
Read article
Peptides9 min read
Intranasal oxytocin: delivery does not settle clinical benefit
Blood, cerebrospinal fluid, brain tissue, and patient outcomes answer different questions about nasal oxytocin.
Read article
Peptides9 min read
Thymosin alpha-1 and vaccine response: does it mean fewer infections?
Antibody findings in vaccine trials are useful, but they do not establish general infection prevention. Explore the human studies and their practical limits.
Read article
TRT9 min read
Revisiting the Anabolic Doc’s Blood-Pressure Video After the FDA Update
The FDA removed cardiovascular boxed-warning language while adding a class-wide blood-pressure warning. That makes careful monitoring more relevant, not less.
Read article
Peptides9 min read
Why small ARA-290 trials leave large safety questions
What ARA-290 trials monitored, which serious events were reported, and why short studies cannot settle uncommon or longer-term risks.
Read article
Supplements9 min read
Tart cherry for recovery: soreness, strength and training adaptation
Tart-cherry trials distinguish less pain, faster strength recovery and lower inflammation. None automatically proves better long-term training adaptation.
Read article338–349 of 600 articles